COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh